Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value.

Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, Esfandiari N, Baracos V, Montano-Loza AJ, Myers RP.

Liver Transpl. 2012 Oct;18(10):1209-16. doi: 10.1002/lt.23495.

2.

Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.

Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM.

J Clin Pharmacol. 2011 Apr;51(4):561-74. doi: 10.1177/0091270010370588. Epub 2010 Jul 9.

PMID:
20622200
3.

Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.

Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, Becker C, Palme MP, Paliard X, Bowersox S, Dennis DM, Druzgala P.

Br J Pharmacol. 2009 Nov;158(6):1536-47. doi: 10.1111/j.1476-5381.2009.00420.x. Epub 2009 Oct 20.

4.

Aging of the nigrostriatal system in the squirrel monkey.

McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLanney LE, Langston WJ, Janson AM.

J Comp Neurol. 2004 Apr 12;471(4):387-95.

PMID:
15022260
5.

Novel observations with FDOPA-PET imaging after early nigrostriatal damage.

Yee RE, Irwin I, Milonas C, Stout DB, Huang SC, Shoghi-Jadid K, Satyamurthy N, Delanney LE, Togasaki DM, Farahani KF, Delfani K, Janson AM, Phelps ME, Langston JW, Barrio JR.

Mov Disord. 2001 Sep;16(5):838-48.

PMID:
11746613
6.

CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: a possible role for ERK activation.

Pulliam L, Irwin I, Kusdra L, Rempel H, Flitter WD, Garland WA.

Brain Res. 2001 Mar 2;893(1-2):95-103.

PMID:
11222997
7.

Ethylenebisdithiocarbamate enhances MPTP-induced striatal dopamine depletion in mice.

McGrew DM, Irwin I, Langston JW.

Neurotoxicology. 2000 Jun;21(3):309-12.

PMID:
10894120
8.

CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties?

Hensley K, Robinson KA, Pye QN, Floyd RA, Cheng I, Garland WA, Irwin I.

Neurosci Lett. 2000 Mar 10;281(2-3):179-82.

PMID:
10704772
9.

Nigrostriatal reduction of aromatic L-amino acid decarboxylase activity in MPTP-treated squirrel monkeys: in vivo and in vitro investigations.

Yee RE, Huang SC, Stout DB, Irwin I, Shoghi-Jadid K, Togaski DM, DeLanney LE, Langston JW, Satyamurthy N, Farahani KF, Phelps ME, Barrio JR.

J Neurochem. 2000 Mar;74(3):1147-57.

10.

Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP.

Walters TL, Irwin I, Delfani K, Langston JW, Janson AM.

Exp Neurol. 1999 Mar;156(1):62-70.

PMID:
10192777
11.

Nigrostriatal monoamine oxidase A and B in aging squirrel monkeys and C57BL/6 mice.

Irwin I, Delanney L, Chan P, Sandy MS, Di Monte DA, Langston JW.

Neurobiol Aging. 1997 Mar-Apr;18(2):235-41.

PMID:
9258902
12.

Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.

Di Monte DA, DeLanney LE, Irwin I, Royland JE, Chan P, Jakowec MW, Langston JW.

Brain Res. 1996 Oct 28;738(1):53-9.

PMID:
8949927
13.

Astrocytes as the site for bioactivation of neurotoxins.

Di Monte DA, Royland JE, Irwin I, Langston JW.

Neurotoxicology. 1996 Fall-Winter;17(3-4):697-703. Review.

PMID:
9086491
14.

GDNF induces a dystonia-like state in neonatal rats and stimulates dopamine and serotonin synthesis.

Beck KD, Irwin I, Valverde J, Brennan TJ, Langston JW, Hefti F.

Neuron. 1996 Mar;16(3):665-73.

15.

Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey.

Forno LS, DeLanney LE, Irwin I, Langston JW.

Adv Neurol. 1996;69:217-28. No abstract available.

PMID:
8615131
16.

Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B.

Finnegan KT, Irwin I, Delanney LE, Langston JW.

J Pharmacol Exp Ther. 1995 May;273(2):716-20.

PMID:
7752075
18.

Aging and the nigrostriatal dopamine system: a non-human primate study.

Irwin I, DeLanney LE, McNeill T, Chan P, Forno LS, Murphy GM Jr, Di Monte DA, Sandy MS, Langston JW.

Neurodegeneration. 1994 Dec;3(4):251-65.

PMID:
7531106
19.

Evolution of nerve fiber degeneration in the striatum in the MPTP-treated squirrel monkey.

Forno LS, DeLanney LE, Irwin I, Langston JW.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):163-70.

PMID:
7888093
20.

Parkinsonism caused by petroleum waste ingestion.

Tetrud JW, Langston JW, Irwin I, Snow B.

Neurology. 1994 Jun;44(6):1051-4.

PMID:
8208398
21.

Rapid ATP loss caused by methamphetamine in the mouse striatum: relationship between energy impairment and dopaminergic neurotoxicity.

Chan P, Di Monte DA, Luo JJ, DeLanney LE, Irwin I, Langston JW.

J Neurochem. 1994 Jun;62(6):2484-7.

PMID:
8189253
22.

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, Langston JW.

Neurology. 1993 Sep;43(9):1698-703.

PMID:
8414015
23.

2-deoxyglucose enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse brain.

Chan P, Langston JW, Irwin I, DeLanney LE, Di Monte DA.

J Neurochem. 1993 Aug;61(2):610-6.

PMID:
8336145
24.

Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.

Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW.

Neurology. 1993 May;43(5):1036-9.

PMID:
8492922
26.

Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.

Graybiel AM, Moratalla R, Quinn B, DeLanney LE, Irwin I, Langston JW.

Adv Neurol. 1993;60:34-9. No abstract available.

PMID:
8420148
27.

MPTP and aging. Studies in the C57BL/6 mouse.

Irwin I, DeLanney LE, Langston JW.

Adv Neurol. 1993;60:197-206. No abstract available.

PMID:
8420136
28.
29.

MPTP-induced ATP loss in mouse brain.

Chan P, DeLanney LE, Irwin I, Langston JW, Di Monte D.

Ann N Y Acad Sci. 1992 May 11;648:306-8. No abstract available.

PMID:
1637060
30.

Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Moratalla R, Quinn B, DeLanney LE, Irwin I, Langston JW, Graybiel AM.

Proc Natl Acad Sci U S A. 1992 May 1;89(9):3859-63.

31.

Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.

Di Monte DA, Wu EY, Delanney LE, Irwin I, Langston JW.

J Pharmacol Exp Ther. 1992 Apr;261(1):44-9.

PMID:
1560384
32.

The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment.

Irwin I, Finnegan KT, Delanney LE, Di Monte D, Langston JW.

Brain Res. 1992 Feb 14;572(1-2):224-31.

PMID:
1611516
33.

Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes.

Di Monte DA, Wu EY, Irwin I, Delanney LE, Langston JW.

Glia. 1992;5(1):48-55.

PMID:
1311704
34.

Astrocytes and Parkinson's disease.

Forno LS, DeLanney LE, Irwin I, Di Monte D, Langston JW.

Prog Brain Res. 1992;94:429-36. Review. No abstract available.

PMID:
1287728
35.

Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes.

Di Monte DA, Wu EY, Irwin I, Delanney LE, Langston JW.

J Pharmacol Exp Ther. 1991 Aug;258(2):594-600.

PMID:
1907660
36.

Does a long preclinical period occur in Parkinson's disease?

Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, Forno L, Ellenberg J, Kurland L, Ruttenber AJ, et al.

Geriatrics. 1991 Aug;46 Suppl 1:8-15. Review. No abstract available.

PMID:
1894149
37.

Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain.

Chan P, DeLanney LE, Irwin I, Langston JW, Di Monte D.

J Neurochem. 1991 Jul;57(1):348-51.

PMID:
2051170
38.

Does a long preclinical period occur in Parkinson's disease?

Koller WC, Langston JW, Hubble JP, Irwin I, Zack M, Golbe L, Forno L, Ellenberg J, Kurland L, Ruttenber AJ, et al.

Neurology. 1991 May;41(5 Suppl 2):8-13. Review. No abstract available.

PMID:
2041599
39.

Mechanism of accumulation of the 1-methyl-4-phenylpyridinium species into mouse brain synaptosomes.

Scotcher KP, Irwin I, DeLanney LE, Langston JW, Di Monte D.

J Neurochem. 1991 May;56(5):1602-7.

PMID:
2013755
40.

The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey.

Irwin I, DeLanney LE, Forno LS, Finnegan KT, Di Monte DA, Langston JW.

Brain Res. 1990 Oct 29;531(1-2):242-52.

PMID:
1981162
41.

Modulating role of dopamine on anesthetic requirements.

Segal IS, Walton JK, Irwin I, DeLanney LE, Ricaurte GA, Langston JW, Maze M.

Eur J Pharmacol. 1990 Sep 4;186(1):9-15.

PMID:
2282937
42.

Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.

Finnegan KT, Skratt JJ, Irwin I, DeLanney LE, Langston JW.

Eur J Pharmacol. 1990 Aug 2;184(1):119-26.

PMID:
2120076
43.

Effects of benzoyltropine and tropacocaine on several cholinergic processes in the rat brain.

Meyer EM, Potter LT, De Vane CL, Irwin I, MacKay SL, Miller R, Ruttenber AJ.

J Pharmacol Exp Ther. 1990 Aug;254(2):584-90.

PMID:
1974643
44.

The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease.

Bloem BR, Irwin I, Buruma OJ, Haan J, Roos RA, Tetrud JW, Langston JW.

J Neurol Sci. 1990 Jul;97(2-3):273-93. Review.

PMID:
2205710
45.

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on ATP levels of mouse brain synaptosomes.

Scotcher KP, Irwin I, DeLanney LE, Langston JW, Di Monte D.

J Neurochem. 1990 Apr;54(4):1295-301.

PMID:
2313288
46.

Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations.

Ricaurte GA, Finnegan KT, Irwin I, Langston JW.

Ann N Y Acad Sci. 1990;600:699-708; discussion 708-10. No abstract available.

PMID:
1701292
47.
48.

The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age.

Finnegan KT, DeLanney LE, Irwin I, Ricaurte GA, Langston JW.

Brain Res. 1989 Sep 4;496(1-2):251-6.

PMID:
2804634
49.

Diethyldithiocarbamate and disulfiram inhibit MPP+ and dopamine uptake by striatal synaptosomes.

Di Monte D, Irwin I, Kupsch A, Cooper S, DeLanney LE, Langston JW.

Eur J Pharmacol. 1989 Jul 4;166(1):23-9.

PMID:
2553428
50.

Evaluation of the neurotoxic potential of N,N-dimethylamphetamine: an illicit analog of methamphetamine.

Ricaurte GA, DeLanney LE, Irwin I, Witkin JM, Katz JL, Langston JW.

Brain Res. 1989 Jun 26;490(2):301-6.

PMID:
2765865

Supplemental Content

Support Center